Brief: Cocrystal Pharma Announces Favorable Safety Data From The Phase 1 Study With Oral Antiviral Cc-42344 That Treats Pandemic, Seasonal Influenza A
17/11/2022 13:26
Nov 17 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA ANNOUNCES FAVORABLE SAFETY DATA FROM THE
PHASE
1 STUDY WITH ORAL ANTIVIRAL CC-42344 FOR THE TREATMENT OF
PANDEMIC AND SEASONAL INFLUENZA A
* COCRYSTAL PHARMA INC - PHASE 2A STUDY OF CC-42344 IS
EXPECTED
TO BE INITIATED IN SECOND HALF OF 2023
Source text for Eikon: ID:nGNX8sz5gn
Further company coverage: COCP.O
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway